Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials

Jennifer W Bea, Qiuhong Zhao, Jane A. Cauley, Andrea Z. Lacroix, Tamsen L Bassford, Cora E. Lewis, Rebecca D. Jackson, Frances A. Tylavsky, Zhao Chen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Loss of lean body mass with aging may contribute to falls and fractures. The objective of this analysis was to determine if taking postmenopausal hormone therapy (or HT: estrogen plus progestogen therapy or estrogen therapy alone) favorably affects age-related changes in lean body mass and if these changes partially account for decreased falls or fractures with HT. Methods: Participants randomly assigned to either estrogen plus progestogen therapy (n = 543) or control (n = 471) and estrogen therapy alone (n = 453) or control (n = 474) and receiving dual-energy X-ray absorptiometry scans to estimate body composition during the Women's Health Initiative were evaluated. Falls and fracture occurrence were obtained by annual self-report. Fractures were confirmed by a clinical chart review. Results: At 6 years postrandomization, lean body mass was not different between HT and control groups. Although lean body mass positively influenced bone mineral density, independent of HT status, the preserved lean body mass observed in the HT arms in the first 3 years did not significantly contribute to models evaluating HT influence on falls and fractures between years 3 and 6. Women taking at least 80% of their medication in the HT arms demonstrated fewer falls compared with placebo; this difference was not attributable to change in lean body mass. Conclusions: Despite early preservation of lean body mass with HT (3 y), HT did not ameliorate long-term (6 y) loss in lean body mass with aging.

Original languageEnglish (US)
Pages (from-to)44-52
Number of pages9
JournalMenopause
Volume18
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Women's Health
Hormones
Estrogens
Progestins
Therapeutics
Annual Reports
Photon Absorptiometry
Body Composition
Bone Density
Self Report
Placebos
Control Groups

Keywords

  • Estrogen plus progestogen therapy
  • Estrogen therapy
  • Falling
  • Fractures.
  • Menopause
  • Muscle

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Effect of hormone therapy on lean body mass, falls, and fractures : 6-year results from the Women's Health Initiative hormone trials. / Bea, Jennifer W; Zhao, Qiuhong; Cauley, Jane A.; Lacroix, Andrea Z.; Bassford, Tamsen L; Lewis, Cora E.; Jackson, Rebecca D.; Tylavsky, Frances A.; Chen, Zhao.

In: Menopause, Vol. 18, No. 1, 01.2011, p. 44-52.

Research output: Contribution to journalArticle

Bea, Jennifer W ; Zhao, Qiuhong ; Cauley, Jane A. ; Lacroix, Andrea Z. ; Bassford, Tamsen L ; Lewis, Cora E. ; Jackson, Rebecca D. ; Tylavsky, Frances A. ; Chen, Zhao. / Effect of hormone therapy on lean body mass, falls, and fractures : 6-year results from the Women's Health Initiative hormone trials. In: Menopause. 2011 ; Vol. 18, No. 1. pp. 44-52.
@article{816027bea712484394e660bec9361cad,
title = "Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials",
abstract = "Objective: Loss of lean body mass with aging may contribute to falls and fractures. The objective of this analysis was to determine if taking postmenopausal hormone therapy (or HT: estrogen plus progestogen therapy or estrogen therapy alone) favorably affects age-related changes in lean body mass and if these changes partially account for decreased falls or fractures with HT. Methods: Participants randomly assigned to either estrogen plus progestogen therapy (n = 543) or control (n = 471) and estrogen therapy alone (n = 453) or control (n = 474) and receiving dual-energy X-ray absorptiometry scans to estimate body composition during the Women's Health Initiative were evaluated. Falls and fracture occurrence were obtained by annual self-report. Fractures were confirmed by a clinical chart review. Results: At 6 years postrandomization, lean body mass was not different between HT and control groups. Although lean body mass positively influenced bone mineral density, independent of HT status, the preserved lean body mass observed in the HT arms in the first 3 years did not significantly contribute to models evaluating HT influence on falls and fractures between years 3 and 6. Women taking at least 80{\%} of their medication in the HT arms demonstrated fewer falls compared with placebo; this difference was not attributable to change in lean body mass. Conclusions: Despite early preservation of lean body mass with HT (3 y), HT did not ameliorate long-term (6 y) loss in lean body mass with aging.",
keywords = "Estrogen plus progestogen therapy, Estrogen therapy, Falling, Fractures., Menopause, Muscle",
author = "Bea, {Jennifer W} and Qiuhong Zhao and Cauley, {Jane A.} and Lacroix, {Andrea Z.} and Bassford, {Tamsen L} and Lewis, {Cora E.} and Jackson, {Rebecca D.} and Tylavsky, {Frances A.} and Zhao Chen",
year = "2011",
month = "1",
doi = "10.1097/gme.0b013e3181e3aab1",
language = "English (US)",
volume = "18",
pages = "44--52",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of hormone therapy on lean body mass, falls, and fractures

T2 - 6-year results from the Women's Health Initiative hormone trials

AU - Bea, Jennifer W

AU - Zhao, Qiuhong

AU - Cauley, Jane A.

AU - Lacroix, Andrea Z.

AU - Bassford, Tamsen L

AU - Lewis, Cora E.

AU - Jackson, Rebecca D.

AU - Tylavsky, Frances A.

AU - Chen, Zhao

PY - 2011/1

Y1 - 2011/1

N2 - Objective: Loss of lean body mass with aging may contribute to falls and fractures. The objective of this analysis was to determine if taking postmenopausal hormone therapy (or HT: estrogen plus progestogen therapy or estrogen therapy alone) favorably affects age-related changes in lean body mass and if these changes partially account for decreased falls or fractures with HT. Methods: Participants randomly assigned to either estrogen plus progestogen therapy (n = 543) or control (n = 471) and estrogen therapy alone (n = 453) or control (n = 474) and receiving dual-energy X-ray absorptiometry scans to estimate body composition during the Women's Health Initiative were evaluated. Falls and fracture occurrence were obtained by annual self-report. Fractures were confirmed by a clinical chart review. Results: At 6 years postrandomization, lean body mass was not different between HT and control groups. Although lean body mass positively influenced bone mineral density, independent of HT status, the preserved lean body mass observed in the HT arms in the first 3 years did not significantly contribute to models evaluating HT influence on falls and fractures between years 3 and 6. Women taking at least 80% of their medication in the HT arms demonstrated fewer falls compared with placebo; this difference was not attributable to change in lean body mass. Conclusions: Despite early preservation of lean body mass with HT (3 y), HT did not ameliorate long-term (6 y) loss in lean body mass with aging.

AB - Objective: Loss of lean body mass with aging may contribute to falls and fractures. The objective of this analysis was to determine if taking postmenopausal hormone therapy (or HT: estrogen plus progestogen therapy or estrogen therapy alone) favorably affects age-related changes in lean body mass and if these changes partially account for decreased falls or fractures with HT. Methods: Participants randomly assigned to either estrogen plus progestogen therapy (n = 543) or control (n = 471) and estrogen therapy alone (n = 453) or control (n = 474) and receiving dual-energy X-ray absorptiometry scans to estimate body composition during the Women's Health Initiative were evaluated. Falls and fracture occurrence were obtained by annual self-report. Fractures were confirmed by a clinical chart review. Results: At 6 years postrandomization, lean body mass was not different between HT and control groups. Although lean body mass positively influenced bone mineral density, independent of HT status, the preserved lean body mass observed in the HT arms in the first 3 years did not significantly contribute to models evaluating HT influence on falls and fractures between years 3 and 6. Women taking at least 80% of their medication in the HT arms demonstrated fewer falls compared with placebo; this difference was not attributable to change in lean body mass. Conclusions: Despite early preservation of lean body mass with HT (3 y), HT did not ameliorate long-term (6 y) loss in lean body mass with aging.

KW - Estrogen plus progestogen therapy

KW - Estrogen therapy

KW - Falling

KW - Fractures.

KW - Menopause

KW - Muscle

UR - http://www.scopus.com/inward/record.url?scp=78651408059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651408059&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e3181e3aab1

DO - 10.1097/gme.0b013e3181e3aab1

M3 - Article

C2 - 20689466

AN - SCOPUS:78651408059

VL - 18

SP - 44

EP - 52

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -